Can This Artificial Pancreas Cure Type-1 Diabetes?

Beta O2 has developed an implantable device, the Better Air Device, which may offer a cure for type 1 diabetes by using real living cells to produce insulin. Unlike a pancreas transplant, it doesn't require immunosuppressants due to engineered protective mechanisms. The device is implanted in the abdomen and requires daily oxygen injections, a minor procedure compared to daily insulin injections. Currently in phase one trials in Sweden, Beta O2 aims to launch in Europe by 2017-2018 and later in the US. The company has raised $21 million but plans further fundraising to expedite market entry. The device targets a multi-billion dollar market with 17 million type 1 diabetics worldwide.

What is the primary advantage of the Beta O2 device over a traditional pancreas transplant?

• It can be used for both type 1 and type 2 diabetes.

• It requires no immunosuppressants.

• It is a non-invasive procedure.

• It is cheaper to produce.

How does the Beta O2 device ensure a sufficient supply of oxygen to the implanted cells?

• Through a solar-powered mechanism.

• Through a built-in oxygen generator.

• By using an external device for daily oxygen injections.

• By absorbing oxygen from the bloodstream.

Where is the Beta O2 device implanted in the body?

• In the chest cavity.

• Near the liver.

• In the abdominal region.

• Under the skin of the arm.

When is the Beta O2 device expected to launch in Europe?

• By 2015.

• Around 2017-2018.

• In 2020.

• By 2025.

What is the estimated market size for type 1 diabetes patients worldwide?

• 25 million patients.

• 17 million patients.

• 10 million patients.

• 5 million patients.